NVO vs ORMP
NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access. ORMP: Oramed is a clinical-stage pharmaceutical company developing oral insulin delivery technology while actively investing in healthcare companies to diversify capital allocation.
Side-by-side fundamentals
| Metric | NVO | ORMP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.19 | $4.02 | |
| Market cap as of 2026-07-23 | $219.8B | $165M | |
| P/E as of 2026-07-23 | 11.78 | 1.50 | ORMP lower |
| PEG as of 2026-07-23 | 16.16 | n/a | |
| Net margin as of 2026-07-23 | +37.2% | -838.4% | NVO higher |
| Gross margin as of 2026-07-23 | +81.8% | n/a | |
| Operating margin as of 2026-07-23 | +45.3% | -1070.4% | NVO higher |
| ROE as of 2026-07-23 | +66.4% | +55.1% | NVO higher |
| ROA as of 2026-07-23 | +23.3% | +49.8% | ORMP higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | ORMP lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | -30.9% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -7.3% | |
| Dividend yield as of 2026-07-23 | +3.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 1.85 | 1.16 | |
| 1-year return as of 2026-07-22 close | -23.8% | +88.7% | ORMP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.